Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KPT-330 has antitumour activity against non-small cell lung cancer.

British journal of cancer - 15 Jul 2014

Sun H, Hattori N, Chien W, Sun Q, Sudo M, E-Ling G L, Ding L, Lim S L, Shacham S, Kauffman M, Nakamaki T, Koeffler H P

Abstract excerpt

BACKGROUND: We investigated the biologic and pharmacologic activities of a chromosome region maintenance 1 (CRM1) inhibitor against human non-small cell lung cancer (NSCLC) cells both in vitro and in vivo. METHODS: The in vitro and in vivo effects of a novel CRM1 inhibitor (KPT-330) for a large n...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Growth Processes
Share to Cisplatin
Share to Exportin 1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to G1 Phase

Share to Hydrazines

Share to Karyopherins

Share to Mice, Inbred NOD

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 24946002
DOI: 10.1038/bjc.2014.260
PMCID: PMC4102938

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24946002-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KPT-330 has antitumour activity against non-small cell lung cancer.PMID 24946002Read ↗

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.Semantic proximity Read ↗

Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.Semantic proximity Read ↗

MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1Semantic proximity Read ↗

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer CellsSemantic proximity Read ↗

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expressionSemantic proximity Read ↗

Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.Semantic proximity Read ↗

<scp>KPT</scp>‐330 inhibitor of <scp>CRM</scp>1 (<scp>XPO</scp>1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of <scp>T</scp>‐cell acute lymphoblastic leukaemia and acute myeloid leukaemiaSemantic proximity Read ↗

BindingDB Entry 2025: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.Semantic proximity Read ↗

Jingfukang induces anti-cancer activity through oxidative stress-mediated DNA damage in circulating human lung cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.